• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Clearmind Medicine Inc. - Common Shares (NQ:CMND)

    1.150 +0.430 (+59.74%)
    Streaming Delayed Price Updated: 1:23 PM EDT, Apr 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Clearmind Medicine Inc. - Common Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Unusual volume stocks are being observed in Monday's session. ↗
    Via Chartmill
    What's going on in today's session ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill
    Top movers in Monday's pre-market session ↗
    Via Chartmill
    News headline image
    Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    These stocks have an unusual volume in today's session ↗
    Via Chartmill
    Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
    Via Chartmill
    News headline image
    These stocks are moving in today's session ↗
    Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session. 
    Via Chartmill
    Topics Artificial Intelligence
    News headline image
    These stocks have an unusual volume in today's session ↗
    On Wednesday, there are stocks with unusual volume. Let's take a look. 
    Via Chartmill
    Topics Artificial Intelligence
    News headline image
    Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Top stock movements in today's session. ↗
    Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
    Via Chartmill
    Topics Artificial Intelligence
    News headline image
    These stocks are moving in today's session ↗
    Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report. 
    Via Chartmill
    Topics Artificial Intelligence
    News headline image
    Tuesday's session: gap up and gap down stocks ↗
    Let's have a look at the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Wondering what's happening in Tuesday's pre-market session? Find an overview in this article. 
    Via Chartmill
    News headline image
    Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Discover the top movers in Friday's pre-market session. ↗
    Wondering what's happening in Friday's pre-market session? Find an overview in this article. 
    Via Chartmill
    News headline image
    Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Files Patent Application in India for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Advances Recruitment for CMND-100 Trial's Third Cohort at Yale, Johns Hopkins and Tel Aviv Sites Following Recent Positive Topline Results
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Moving Forward to the Next Stage of Its Clinical Trial Following Data and Safety Monitoring Board Approval
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation
    From Polyrizon Ltd.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    News headline image
    Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100
    From Clearmind Medicine Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    13 14 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.